甲磺酸阿帕替尼片联合紫杉醇注射剂和顺铂注射剂治疗非小细胞肺癌的临床研究

A Clinical Study of Apatinib Mesylate Tablets Combined with Paclitaxel Injection and Cisplatin Injection in the Treatment of Non-small Cell Lung Cancer

目的分析甲磺酸阿帕替尼片联合紫杉醇注射剂和顺铂注射剂治疗非小细胞肺癌的临床治疗效果。方法选取2018年9月—2019年9月入院治疗的50例非小细胞肺癌患者,随机分组。常规组25例,给予紫杉醇注射剂和顺铂注射剂治疗;观察组25例,在常规组治疗基础上加用甲磺酸阿帕替尼片。对比KPS评分、细胞因子水平、临床疗效。结果观察组治疗后KPS评分(75.71±5.49)分明显高于常规组(70.35±5.23)分,差异有统计学意义(t=3.534,P<0.001);观察组治疗后CYFRA21-1(细胞角蛋白19片段)、NSE(神经元特异性烯醇化酶)、CA125(癌抗原125)和MMP-9(基质金属蛋白酶-9)水平为(22.01±3.82)、(5.83±1.13)、(49.15±5.01)、(1042.89±206.71)ng/mL,均低于常规组(25.84±4.31)、(9.61±2.41)、(85.61±5.48)、(1342.24±241.00)ng/mL,差异有统计学意义(t=3.325、7.101、24.552、4.714,P<0.05);观察组总缓解率96.00%,明显高于常规组72.00%,差异有统计学意义(χ^(2)=5.357,P=0.021)。结论非小细胞肺癌患者采用甲磺酸阿帕替尼片联合紫杉醇注射剂和顺铂注射剂治疗,能够有效提升患者的KPS评分,改善患者的细胞因子水平。

Objective To analyze the clinical therapeutic effect of apatinib mesylate tablets combined with paclitaxel injection and cisplatin injection in the treatment of non-small cell lung cancer.Methods 50 patients with non-small cell lung cancer who were admitted to the hospital from September 2018 to September 2019 were selected and routine divided into groups.25 patients in the routine group were treated with paclitaxel injection and cisplatin injection;25 patients in the observation group were treated with apatinib mesylate tablets on the basis of the routine group treatment.Compared the KPS scores、cytokine levels and clinical efficacy.Results The KPS score(75.71±5.49)points of the observation group after treatment was significantly higher than that of the routine group(70.35±5.23)points,and the difference was statistically significant(t=3.534,P<0.001);the observation group after treatment CYFRA21-1(cytokeratin 19 fragments),NSE(neuron specific enolase),CA125(cancer antigen 125)and MMP-9(matrix metalloproteinase-9)levels are(22.01±3.82)ng/mL,(5.83±1.13)ng/mL,(49.15±5.01)ng/mL,(1042.89±206.71)ng/mL,all lower than the routine group(25.84±4.31)ng/mL,(9.61±2.41)ng/mL,(85.61±5.48)ng/mL,(1342.24±241.00)ng/mL,the difference was statistically significant(t=3.325,7.101,24.552,4.714,P<0.05);the total remission rate of the observation group was 96.00%,which was significantly higher than that of the routine group 72.00%,the difference was statistically significant(χ^(2)=5.357,P=0.021).Conclusion The treatment of non-small cell lung cancer patients with apatinib mesylate tablets combined with paclitaxel injection and cisplatin injection can effectively improve the patient's KPS score and improve the patient's cytokine level.